Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Therapy for Rare Spinal Muscular Atrophy Receives FDA Approval



The drug is the first to be approved to treat the rare genetic disease in both adults and children.

Share this!

January 5, 2017 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) has approved Biogen’s Spinraza for the treatment of spinal muscular atrophy (SMA). The drug is the first to be approved to treat the rare genetic disease in both adults and children.

“There has been a long-standing need for a treatment for spinal muscular atrophy, the most common genetic cause of death in infants, and a disease that can affect people at any stage of life,” said Dr. Billy Dunn, director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “As shown by our suggestion to the sponsor to analyze the results of the study earlier than planned, the FDA is committed to assisting with the development and approval of safe and effective drugs for rare diseases and we worked hard to review this application quickly; we could not be more pleased to have the first approved treatment for this debilitating disease.”

SMA is characterized by a loss of lower motor neurons, which are responsible for controlling movement, and results in muscle weakness. While the symptoms of the disease vary between individuals, it is often fatal. The incidence of SMA is approximately 1 in every 10,000 live births.

Spinraza was tested in a randomized controlled clinical trial of 121 patients with infantile-onset SMA. An interim analysis found that 40 percent of patients treated with Spinraza saw improvement in motor milestones – such as head control, sitting, rolling, standing and walking – compared to the control group.

Biogen has set the price of the injectable at $125,000 per treatment, which could see patients and payers facing bills up to $750,000 for their first year of treatment with Spinraza. The price would likely decrease to $375,000 for subsequent years, based on the number of treatments necessary, however the drug would likely be taken on a long-term basis.

The cost of Spinraza is surprisingly consistent with other recently-released rare disease drugs. Last year, Gilead Sciences’ hepatitis C drug, Sovaldi, drew criticism over its $84,000 price for a 12-week treatment course. However, the difference between the drugs is that Sovaldi is essentially a cure for some genotypes of hepatitis C; Spinraza has only been shown to improve motor function in some patients with SMA.

Keywords: FDA, Rare Disease, Drug Pricing


Share this with your colleagues!

Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News

FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News

One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


Top 5 Most Impactful Tweets in Life Sciences During the Last Week


EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider

Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology

Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn

eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.